



MEDISTEP HEALTHCARE LIMITED

CIN- U21009GJ2023PLC141841

Regd. Off: 05,S.NO-245/B,PLOT-19,T.PNR.A-ONE HOTEL, N.H.-8,NA, Narol,
Ahmedabad, Ahmadabad City, Gujarat, India, 382405

Website: <http://medistepphc.com>

Email: medistephealthcare.ltd@gmail.com

Mo: 8460768695

Date: 11-11-2025

To,
National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor |
Plot No. C/1, G Block Bandra - Kurla Complex
Bandra (E), Mumbai – 400051

Symbol: MEDISTEP
ISIN: INE0UOY01019

Subject: Outcome of the Board Meeting under Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that the Board of Directors of Medistep Healthcare Limited at their meeting held on **Tuesday, 11th November, 2025** at the Registered Office of the Company situated at 05, S.No-245/B, Plot-19, T.P.S. 56, Free Way Trade Center, NR. A-One Hotel, N.H.-8, Narol Gam, Narol, Ahmedabad, Daskroi, Gujarat-382405 has inter alia, considered and approved the Standalone Un-audited Financial Results of the Company for the Half Year ended 30th September, 2025.

We enclose herewith a copy of the said Financial Results along with the Limited Review Report by the Statutory Auditors of the Company.

The meeting of Board of Directors commenced at 03:00 P.M. and concluded at 4:00 P.M.

You are requested to take the same on your record.

Thanking you,
Yours faithfully,

**For and on behalf of
Medistep Healthcare Limited**

**Girdhari Lal Prajapat
Managing Director
DIN: 09513249**

Encl. as above

Medistep Healthcare Limited

CIN: U21009GJ2023PLC141841

Regd. Office : 05, S.No-245/B, Plot-19, T.P.S. 56, Free Way Trade Center, Nr. A-One Hotel, N.H.-8, Narol Gam, Narol, Ahmedabad, Daskroi, Gujarat, India, 382405

Website: www.medistephc.com Email: Info@medistephc.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30 SEPTEMBER, 2025

Rs. In Lakhs

S.No	Particulars	Six months ended			Year ended	
		30-09-2025	31-03-2025	30-09-2024	31.03.2025	31.03.2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)
1	Income					
	a) Revenue from operations	3,506.88	2,840.32	2,125.17	4,965.48	3,161.51
	b) Other income	0.16	0.16	0.22	0.37	1.01
	Total income	3,507.04	2,840.47	2,125.38	4,965.86	3,162.52
2	Expenses					
	a) Purchase of stock in trade	2,591.75	2,055.75	1,477.85	3,533.60	2,760.52
	b) Cost of material consumed	714.56	439.51	403.08	842.59	63.97
	c) (Increase)/decrease in the inventories of work in progress & finished goods	-242.21	-13.21	-7.26	-20.47	-86.75
	d) Employee benefits expense	12.63	13.42	11.54	24.97	12.04
	e) Finance cost	0.32	0.64	2.39	3.03	5.98
	f) Depreciation and amortisation expense	1.34	1.66	1.66	3.32	2.08
	g) Other expenses	31.64	14.55	10.50	25.05	15.44
	Total expenses	3,110.03	2,512.31	1,899.77	4,412.09	2,773.28
3	Profit/(loss) before exceptional item & tax (1-2)	397.01	328.16	225.61	553.77	389.23
4	Exceptional Items	-	-	-	-	-
5	Profit/(loss) before tax (3-4)	397.01	328.16	225.61	553.77	389.23
6	Tax expense	99.92	82.59	56.78	139.37	99.27
7	Net Profit/(Loss) after tax (5-6)	297.09	245.57	168.83	414.40	289.96
8	Paid-up Equity Share Capital (Face value of Rs.10/- each)	142.10	104.66	104.66	104.66	236.75
9	Other Equity (excluding revaluation reserve)				688.66	730.88
10	Earnings per share (of Rs.10/- each) Basic & Diluted (Rs.)	2.61	2.38	1.69	4.01	39.74

Notes:-

- The above Financial Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their meeting held on 11th November, 2025.
- The above results have been prepared in accordance with the recognition and measurement principles of Accounting Standard ("AS"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- The results for the half year ended September 30, 2025 are reviewed by the statutory auditor of the company in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
As per the Accounting Standard - 17 on "Segment Reporting", the Company is primary engaged in a single business activity, and its operations are confined within India. Hence, there are no separate reportable business or geographical segments requiring disclosure in the financial statements.
The Company presents Standalone Financial Results, as it does not have any Subsidiary, Associate, or joint Venture as on September 30, 2025
- The company has issued 37,44,000 equity shares of Rs 10 each at a premium of Rs 33 each as fresh issue by way of public issue and get listed on EMERGE Platform of National Stock Exchange of India Limited on August 18, 2025. The Company has utilised proceeds from IPO as per the object clause of the prospectus as detailed below:

Rs. In Lakhs

S No.	Object of the Issue	Amount allotted for the object	Amount utilized till 30th September 2025	Amount unutilized till 30th September 2025	Deviation (if any)
a	Capital Expenditure Requirement	50.75	-	50.75	-
b	Working Capital Requirement	1,234.17	1,234.17	-	-
c	General corporate purpose	164.01	164.01	-	-
d	Public issue related expenses	160.99	160.99	-	-
	Total	1,609.92	1,559.17	50.75	-

6 The figures for the previous period/year have been regrouped / rearranged / reclassified wherever necessary.

For and on Behalf of
Medistep Healthcare Limited

Girdhari Lal Prajapat
Managing Director
DIN: 09513249
Date: November 11, 2025
Place: Ahmedabad

Medistep Healthcare Limited

CIN: U21009GJ2023PLC141841

Regd. Office : 05, S.No-245/B, Plot-19, T.P.S. 56, Free Way Trade Center, Nr. A-One Hotel, N.H.-8, Narol Gam, Narol, Ahmedabad, Daskroi, Gujarat, India, 382405

Website: www.medistephc.com Email: Info@medistephc.com

STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30 SEPTEMBER, 2025

Rs. In Lakhs

Particulars	For the Half year Ended 30.09.2025	For the year ended 31.03.2025
A. Cash flow from operating activities		
Profit/(loss) before tax	397.01	553.77
Adjustments for :		
Depreciation and amortisation expense	1.34	3.32
Interest expenses	0.32	3.03
Provision for long term employee benefits	0.75	1.56
Profit on Sales of Shares	(0.10)	-
	399.32	561.66
Changes in assets and liabilities		
Decrease /(Increase) in Inventories	(385.38)	(16.67)
Decrease / (Increase) in Trade Receivable	(1,648.65)	(636.40)
Decrease / (Increase) in Long Term Loans and Advances	-	-
Decrease / (Increase) in Short Term Loans and Advances	(16.48)	(16.09)
Decrease / (Increase) in Other Assets	7.53	(7.81)
Increase / (Decrease) in Trade Payables	122.40	104.32
Increase / (Decrease) in Short Term Provisions	(0.62)	1.23
Increase / (Decrease) in Long Term Provisions	-	-
Increase / (Decrease) in Other Liabilities	4.91	12.14
Cash (used) /generated from operations	(1,516.99)	2.38
Taxes paid (net of refunds)	(0.20)	(0.25)
Net cash (used in)/from operating activities (A)	(1,517.19)	2.13
B. Cash Flow from Investing Activities		
Purchase of property, plant and equipment	-	-
Investment made	0.25	-
Net cash generated from/(used in) investing activities (B)	0.25	-
C. Cash flows from financing activities		
Interest & Finance Cost	(0.32)	(3.03)
Proceeds from issues of equity shares (net of issue expenses)	1,448.93	100.00
(Repayments) / proceeds of long term borrowings	-	-
(Repayments) / proceeds of short term borrowings	(4.57)	30.93
Net cash generated from/(used in) financing activities (C)	1,444.04	127.90
Net increase/ (decrease) in cash and cash equivalents (A+B+C)	(72.90)	130.03
Cash and cash equivalents at the beginning of the period/year	131.01	0.97
Cash and cash equivalents at the end of the period/year	58.10	131.01
Cash and cash equivalents comprise of:		
Cash on hand	6.62	2.18
Balance with banks		
- in current accounts	51.48	0.02
Cheque in Hand		128.81
Total	58.10	131.01

**For and on Behalf of
Medistep Healthcare Limited****Girdhari Lal Prajapat
Managing Director**

DIN: 09513249

Date: November 11, 2025

Place: Ahmedabad